EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessment of a Modified High‐Dimensional Propensity Score Approach for UK Electronic Health Record Data: Evaluating Upper Gastrointestinal Safety of NSAIDs and COX ‐2 Inhibitors

John Tazare iD, Daniel C Gibbons iD, Liam Smeeth, M Sanni Ali, Iain A Gillespie, Marianne Cunnington, John Logie, Ian J Douglas, Elizabeth J Williamson

Pharmacoepidemiology and Drug Safety · 2026

DOI: 10.1002/pds.70319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von John Tazare und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Cyclooxygenase 2 Inhibitors, Electronic Health Records, Propensity Score. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study extends a version of the high‐dimensional propensity score (HDPS) recently modified for the UK electronic health record setting, by enriching primary care data with hospital data. The performance of this modified approach is assessed via the estimation of a well‐established association, the reduced risk of upper gastrointestinal bleeding (UGIB) in cyclo‐oxygenase‐2 inhibitor (COX‐2i) users versus non‐steroidal anti‐inflammatory drug (NSAID) users.

Methods

We conducted an active‐comparator, new‐user cohort study using UK primary care data from the Clinical Practice Research Datalink GOLD database, with linkages to hospitalisation and mortality records. We included individuals with osteoarthritis initiating NSAIDs or COX‐2is between 2000–2004. We used Cox proportional hazards models to estimate the hazard ratio (HR) for UGIB, adjusting for confounders using investigator‐specified and HDPS‐derived propensity scores. Sensitivity analyses were conducted varying the number of HDPS covariates included and the covariate assessment period.

Results

We identified 74 443 and 25 742 new users of NSAID and COX‐2i users, respectively. The unadjusted HR for UGIB comparing COX‐2i and NSAID users was 1.28 (95% CI: 0.95–1.72). Of the included HDPS covariates, 26% originated from the hospitalisation dimension, a source not considered in previous applications indicating the considerable information contained in these data on proxies of potential confounders. The modified‐HDPS obtained similar results to the other studies, shifting the HR closer to the expected association (HR 0.86; 95% CI: 0.58–1.26).

Conclusion

We demonstrate the ability of the modified‐HDPS to obtain similar results to comparable pharmacoepidemiological studies and randomised trials, highlighting the potential benefit of these approaches in UK EHRs more widely and the value of adding hospital data to enrich the pool of covariates available for the HDPS algorithm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 InhibitorsElectronic Health RecordsPropensity ScoreGastrointestinal HemorrhageHumansUnited KingdomFemaleMaleAgedMiddle AgedProportional Hazards ModelsCohort StudiesDatabases, FactualOsteoarthritisPrimary Health CareHospitalization

Stichwörter der Autor:innen

confounder adjustmentelectronic health recordshigh dimensional propensity score

Substanzen

Anti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 Inhibitors

Autor:innen und Institutionen

  • Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
  • Real-World Data Measurement & Analytics, GSK, London, UK.
  • GSK, London, UK.
  • Analysis Group Inc., London, UK.

ORCID-Profile: John Tazare, Daniel C Gibbons

Förderung

  • Wellcome Trust
  • Medical Research Council

Zitieren

APA

Tazare, J., Gibbons, D. C., Smeeth, L., Ali, M. S., Gillespie, I. A., Cunnington, M., Logie, J., Douglas, I. J., & Williamson, E. J. (2026). Assessment of a Modified High‐Dimensional Propensity Score Approach for UK Electronic Health Record Data: Evaluating Upper Gastrointestinal Safety of NSAIDs and COX ‐2 Inhibitors. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70319

Vancouver

Tazare J, Gibbons DC, Smeeth L, Ali MS, Gillespie IA, Cunnington M, et al. Assessment of a Modified High‐Dimensional Propensity Score Approach for UK Electronic Health Record Data: Evaluating Upper Gastrointestinal Safety of NSAIDs and COX ‐2 Inhibitors. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70319

BibTeX
@article{Tazare2026,
  author = {Tazare, John and Gibbons, Daniel C and Smeeth, Liam and Ali, M Sanni and Gillespie, Iain A and Cunnington, Marianne and Logie, John and Douglas, Ian J and Williamson, Elizabeth J},
  title = {Assessment of a Modified High‐Dimensional Propensity Score Approach for UK Electronic Health Record Data: Evaluating Upper Gastrointestinal Safety of NSAIDs and COX ‐2 Inhibitors},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  doi = {10.1002/pds.70319}
}
Kostenlos starten →